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Abstract
We present a case of a 77-year old female who had undergone a coronary artery bypass grafting with an aortic
valve replacement and developed three month later a Methicillin-Resistant Staphylococcus aureus (MRSA) sternal
wound infection which was successful treated with Daptomycin combined with vacuum-assisted closure (VAC).
Introduction
Sternal wound infection is a severe complication in car-
diac surgery despite continuing efforts to improve perio-
perative conditions. This complication is often
associated with significant morbidity and mortality rates
of up to 45% [1], with prolonged hospitalization [2] and
additional surgical procedures, as well as prolonged anti-
biotic therapy and its inherent high costs [3]. The most
common conventional treatments involve surgical revi-
sion, open dressing, closed mediastinal irrigation, debri-
dement, complete sternectomy, or reconstruction with
omental or muscleflaps [4]. With the increase of MRSA
infection, the accompanying antibiotic therapy has
received more attention for treatment of sternal wound
infections after cardiac surgery.
Case Report
A 77-year-old female was admitted with coronary artery
disease and severe aortic stenosis to the Department of
Cardiac Surgery of the University Hospital of Goettin-
gen, Germany in July of 2007. A coronary artery bypass
grafting (left anterior descending artery was revascular-
ized by the left internal mammarian artery) and an aor-
tic valve replacement (Cryolife O’Brien® 23 mm,
biological) were performed. After an uneventful opera-
tion and postoperative course, the patient was dis-
charged home. Three month after discharge, at the
initial postoperative visit, physical examination revealed
an unstable sternum with purulent drainage (MRSA-
positive) from the distal portion of the incision. Subse-
quently, the patient was hospitalized and started on
wide broad spectrum antibiotics (Clindamycin and
Rifampicin) in combination with local antiseptic wash-
ings. She was urgently taken to the operating room for
wound debridement. Once the incision was reopened,
frank pus was noted. The wound was irrigated and the
sternum was realigned. Her general condition recovered
and two months after the operation, the patient was dis-
charged home.
One month following this, the patient returned with
purulent drainage forming in the distal wound, necessi-
tating hospital readmission with intravenous antibiotics
(Vancomycin 500 mg/d, for 10 days). Given the prior
presentation of an unstable sternum, we elected to
remove three sternal wires. A vacuum-assisted closure
(VAC) was placed along with Alginat to promote sec-
ondary wound healing. On the 26
th postoperative day,
the patient was discharged home with instructions to
return for clinic three-times-per-week for wound care.
One month following this, eight months since the
initial surgery, the wound was not fully healed. Although
there was some evidence of secondary degree healing, it
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remaining two sternal wires. Therefore, each sternal
wire was removed, the wound was widely debridement
of infected tissues, and a VAC was placed the entire
length of the incision (Figure 1). This resulted in further
wound healing and the patient was again discharged
home with wound care.
In March 2009, twenty months since the initial surgery,
the patient presented with yet another sternal wound
dehiscence. When the wound was probed, a fistula was
noted to the mediastinum. She readmitted to the hospital
and brought to the operating room for wound irrigation
with VAC placement. Bacterial cultures obtained intrao-
peratively grew MRSA and the antibiogram presented
resistance to several conventional antibiotics but displayed
sensitivity to the new antibiotic drug Daptomycin (Cubi-
cin®, Novartis Pharma GmbH, Germany). Daptomycin (4
mg/kg/day) was administered and total duration of appli-
cation was ten days. The wound eventually healed with no
residual fistula or infection of MRSA (Figure 2) and she
was discharged on the 18th postoperative day. A follow-up
visit in May 2010 in our ambulance revealed no indication
of bacterial colonization in latest microbiological tests.
The patient is free of pain and able to function well in
daily life.
Discussion
The incidence of sternal wound infection after cardiac
surgery is reported to be 0.4-5% [5] and Staphylococcus
aureus is the most common pathogen isolated from
sternal wound infections after cardiac surgery as well as
from bacteraemic blood cultures [6]. An increasing
trend in antibiotic resistance, with the appearance of
progressively more cases of MRSA strain infections have
been shown in epidemiological studies [6,3]. Sternal
infection with S. aureus is associated with high morbid-
ity and mortality and carries a worse prognosis than
that of other aetiologies [7].
Vancomycin remains the reference standard for the
treatment of systemic infection caused by methicillin resis-
tant Staphylococcus aureus ( M R S A ) .H o w e v e r ,t h e r ea r e
many reasons for clinical failure of Vancomycin [8,9],
therefore the need for alternative therapies that target
MRSA has become apparent. One alternative is Linezolid,
because it has been shown that this antibiotic drug in ret-
rospective evaluations of complicated skin and soft-tissue
infections (SSTIs) caused by MRSA, compared with Van-
comycin, is associated with significantly higher clinical
cure rates and reduced lengths of hospitalization [10,11].
Despite the apparent advantages of Linezolid in the treat-
ment of MRSA infections, concerns about safety and costs
of therapy often limit its use.
Figure 1 Postoperative sternal wound infection eight months
since the initial surgery. The remaining two sternal wires were
removed. After removing sternal wires, reapplication of VAC therapy
was initiated.
Figure 2 The wound eventually healed with no residual fistula
or infection of MRSA, twenty-one months since the initial
surgery.
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activity against MRSA in a concentration-dependent
manner [12]. The difference between Daptomycin and
standard therapy in the treatment of MRSA infections
was up to now not statistically significant, however Dap-
tomycin has already been proven to be effective in the
treatment of bacteremia and endocarditis caused by
MRSA and several case reports about its effectiveness in
the field of cardiac surgery exist in the literature
[13-17]. Based on these observations, Daptomycin may
offer a possible new treatment option for surgical man-
agement of MRSA sternal wound infection after cardiac
surgery combined with surgical therapy.
In our case the patient was re-submitted to our hospital
with generalized colonization and infection with MRSA.
Standard therapy concerning antibiotic treatment has
failed to eradicate the MRSA, so that we decided for an
alternative antimicrobial strategy in the form of Daptomy-
cin application. However, its longterm efficacy in cardiac
surgery should be further evaluated in a controlled setting.
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